MedTrace Logo

Assessment of the Prevalence of Olfactory Disorders in Systemic Scleroderma

NCT04178616 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2020-11-19

No results posted yet for this study

Summary

Prospective monocentric study of patients with systemic sclerosis disease.

The primary outcome is to define the prevalence of olfactory disorders (hyposmia and anosmia) in systemic sclerosis disease.

The secondary outcomes are:

* To assess the correlation of olfaction disorders with clinical and biological and factors related to systemic sclerosis patients.
* To estimate the frequency of sinonasal disorders in patients with systemic sclerosis disease

Conditions

  • Olfactory Disorders
  • Scleroderma

Interventions

DIAGNOSTIC_TEST

olfactory testing with specific odorants (localisation and identification)

Olfactory testing : ETOC (European Test of Olfactory capabilities)

Sponsors & Collaborators

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • David Launay, MD,PhD · University Hospital, Lille

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-31
Primary Completion
2020-03-13
Completion
2020-03-13

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04178616 on ClinicalTrials.gov